Concepts (314)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 44 | 2011 | 839 | 2.590 |
Why?
|
| Pancreas Transplantation | 13 | 2004 | 71 | 2.060 |
Why?
|
| Immunosuppressive Agents | 14 | 2009 | 514 | 1.080 |
Why?
|
| Graft Rejection | 16 | 2009 | 458 | 0.760 |
Why?
|
| Kidney | 15 | 2011 | 945 | 0.680 |
Why?
|
| Tissue Donors | 8 | 2011 | 195 | 0.660 |
Why?
|
| Cyclosporine | 7 | 2006 | 121 | 0.610 |
Why?
|
| Sirolimus | 4 | 2009 | 118 | 0.590 |
Why?
|
| Graft Survival | 13 | 2003 | 465 | 0.540 |
Why?
|
| Nephrectomy | 6 | 2011 | 103 | 0.520 |
Why?
|
| Kidney Diseases | 2 | 2011 | 307 | 0.500 |
Why?
|
| Diabetes Mellitus, Type 1 | 4 | 1998 | 529 | 0.440 |
Why?
|
| Postoperative Complications | 10 | 2004 | 1615 | 0.390 |
Why?
|
| Thrombosis | 5 | 2004 | 218 | 0.370 |
Why?
|
| Albuminuria | 1 | 2011 | 171 | 0.360 |
Why?
|
| Cadaver | 7 | 2004 | 136 | 0.320 |
Why?
|
| Mycophenolic Acid | 3 | 2006 | 62 | 0.310 |
Why?
|
| Living Donors | 4 | 2007 | 160 | 0.290 |
Why?
|
| Blood Pressure | 3 | 2011 | 1451 | 0.260 |
Why?
|
| Time Factors | 14 | 2011 | 4655 | 0.260 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2004 | 15 | 0.240 |
Why?
|
| Humans | 59 | 2011 | 68618 | 0.230 |
Why?
|
| Cytomegalovirus Infections | 3 | 2004 | 69 | 0.230 |
Why?
|
| Antibodies, Monoclonal | 4 | 2007 | 511 | 0.230 |
Why?
|
| Treatment Outcome | 16 | 2009 | 7029 | 0.220 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 1999 | 185 | 0.220 |
Why?
|
| Adult | 30 | 2011 | 21403 | 0.210 |
Why?
|
| Male | 36 | 2011 | 37321 | 0.210 |
Why?
|
| Female | 38 | 2011 | 38074 | 0.200 |
Why?
|
| Hypertension | 1 | 2011 | 1535 | 0.200 |
Why?
|
| Retrospective Studies | 13 | 2005 | 7277 | 0.200 |
Why?
|
| Follow-Up Studies | 11 | 2004 | 3259 | 0.190 |
Why?
|
| Creatinine | 7 | 2006 | 243 | 0.190 |
Why?
|
| Diabetic Nephropathies | 3 | 1998 | 161 | 0.180 |
Why?
|
| Urinary Bladder | 3 | 1998 | 108 | 0.180 |
Why?
|
| Drainage | 2 | 1998 | 133 | 0.180 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 1999 | 9 | 0.180 |
Why?
|
| Exophiala | 1 | 1999 | 4 | 0.170 |
Why?
|
| Nocardia Infections | 1 | 1999 | 8 | 0.170 |
Why?
|
| Kidney Failure, Chronic | 3 | 1994 | 365 | 0.170 |
Why?
|
| Mycoses | 1 | 1999 | 60 | 0.160 |
Why?
|
| Propylene Glycols | 2 | 2009 | 16 | 0.160 |
Why?
|
| Colitis | 1 | 1999 | 156 | 0.160 |
Why?
|
| Risk Factors | 9 | 2011 | 5731 | 0.150 |
Why?
|
| Exudates and Transudates | 1 | 1997 | 25 | 0.150 |
Why?
|
| Postoperative Care | 1 | 1998 | 163 | 0.140 |
Why?
|
| Short Bowel Syndrome | 1 | 1996 | 15 | 0.140 |
Why?
|
| Intestinal Diseases | 1 | 1996 | 25 | 0.140 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 1997 | 101 | 0.140 |
Why?
|
| Obesity | 1 | 2003 | 1076 | 0.140 |
Why?
|
| Sphingosine | 2 | 2009 | 315 | 0.130 |
Why?
|
| Intestine, Small | 1 | 1996 | 89 | 0.130 |
Why?
|
| Transplantation, Homologous | 6 | 1998 | 242 | 0.130 |
Why?
|
| Acyclovir | 1 | 1995 | 38 | 0.130 |
Why?
|
| Epitopes | 2 | 1994 | 146 | 0.130 |
Why?
|
| Renal Veins | 2 | 2000 | 18 | 0.130 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1995 | 52 | 0.130 |
Why?
|
| Middle Aged | 21 | 2011 | 21147 | 0.130 |
Why?
|
| South Carolina | 6 | 2011 | 2752 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 2 | 2011 | 274 | 0.120 |
Why?
|
| Hypertension, Renovascular | 1 | 1995 | 47 | 0.120 |
Why?
|
| Ischemia | 6 | 1994 | 229 | 0.120 |
Why?
|
| Regression Analysis | 2 | 2011 | 737 | 0.110 |
Why?
|
| Urethra | 1 | 1994 | 56 | 0.110 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2006 | 49 | 0.110 |
Why?
|
| Acute Kidney Injury | 3 | 1992 | 232 | 0.110 |
Why?
|
| Liver Transplantation | 4 | 1999 | 400 | 0.110 |
Why?
|
| Thrombectomy | 3 | 2004 | 238 | 0.100 |
Why?
|
| Partial Thromboplastin Time | 2 | 2003 | 57 | 0.100 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2004 | 73 | 0.090 |
Why?
|
| Child | 7 | 2004 | 6405 | 0.090 |
Why?
|
| Pancreas | 2 | 2004 | 225 | 0.090 |
Why?
|
| Diverticulitis, Colonic | 1 | 1990 | 10 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 546 | 0.090 |
Why?
|
| Intestinal Perforation | 1 | 1990 | 35 | 0.090 |
Why?
|
| Delayed Graft Function | 1 | 2009 | 39 | 0.080 |
Why?
|
| Tissue Preservation | 2 | 1997 | 44 | 0.080 |
Why?
|
| Child, Preschool | 4 | 2004 | 3187 | 0.080 |
Why?
|
| Reperfusion | 1 | 1989 | 78 | 0.080 |
Why?
|
| Age Factors | 3 | 2011 | 1864 | 0.080 |
Why?
|
| Cause of Death | 4 | 1999 | 241 | 0.080 |
Why?
|
| Renal Dialysis | 3 | 1996 | 174 | 0.080 |
Why?
|
| Organ Preservation | 2 | 1994 | 69 | 0.080 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2007 | 3 | 0.070 |
Why?
|
| CD11a Antigen | 1 | 2007 | 3 | 0.070 |
Why?
|
| Infant | 5 | 2004 | 2891 | 0.070 |
Why?
|
| Adenosine Triphosphate | 1 | 1989 | 314 | 0.070 |
Why?
|
| Intestines | 2 | 1998 | 114 | 0.070 |
Why?
|
| Acute Disease | 4 | 2000 | 658 | 0.070 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 1986 | 4 | 0.070 |
Why?
|
| Prevalence | 1 | 2011 | 1619 | 0.070 |
Why?
|
| Blood Volume | 1 | 1986 | 47 | 0.070 |
Why?
|
| Sodium Chloride | 1 | 1986 | 136 | 0.070 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2005 | 35 | 0.070 |
Why?
|
| Biopsy | 2 | 2005 | 540 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2011 | 2007 | 0.060 |
Why?
|
| Adolescent | 9 | 2005 | 8912 | 0.060 |
Why?
|
| Ganciclovir | 1 | 2004 | 27 | 0.060 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 2279 | 0.060 |
Why?
|
| Opportunistic Infections | 1 | 2004 | 33 | 0.060 |
Why?
|
| Hemodilution | 1 | 1983 | 9 | 0.060 |
Why?
|
| Logistic Models | 2 | 1998 | 1420 | 0.060 |
Why?
|
| Hydroxyethyl Starch Derivatives | 1 | 1983 | 24 | 0.060 |
Why?
|
| Immunosorbents | 1 | 1983 | 1 | 0.060 |
Why?
|
| Starch | 1 | 1983 | 18 | 0.060 |
Why?
|
| Lymph | 1 | 1983 | 8 | 0.060 |
Why?
|
| Antibody Specificity | 1 | 1983 | 98 | 0.060 |
Why?
|
| Antigens | 1 | 1983 | 90 | 0.060 |
Why?
|
| Microbodies | 2 | 1994 | 60 | 0.050 |
Why?
|
| Laparoscopy | 2 | 2006 | 237 | 0.050 |
Why?
|
| Survival Rate | 3 | 2009 | 1056 | 0.050 |
Why?
|
| Thromboembolism | 1 | 2003 | 91 | 0.050 |
Why?
|
| Lymphocytes | 1 | 1983 | 228 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2004 | 211 | 0.050 |
Why?
|
| Antigen-Antibody Complex | 1 | 1983 | 175 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2003 | 127 | 0.050 |
Why?
|
| Immune Sera | 1 | 1981 | 30 | 0.050 |
Why?
|
| Drug Therapy, Combination | 3 | 2009 | 649 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 2 | 1999 | 376 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2001 | 714 | 0.050 |
Why?
|
| Skin Transplantation | 1 | 1981 | 45 | 0.050 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 1996 | 31 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2001 | 82 | 0.050 |
Why?
|
| Catheterization | 3 | 2004 | 209 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2003 | 631 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2001 | 114 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2003 | 867 | 0.040 |
Why?
|
| Factor V | 1 | 2000 | 20 | 0.040 |
Why?
|
| Renal Artery Obstruction | 1 | 2000 | 29 | 0.040 |
Why?
|
| Arm | 1 | 1999 | 59 | 0.040 |
Why?
|
| Pain, Postoperative | 1 | 2001 | 214 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2000 | 125 | 0.040 |
Why?
|
| Metabolic Clearance Rate | 1 | 1998 | 48 | 0.040 |
Why?
|
| Fingolimod Hydrochloride | 2 | 2009 | 24 | 0.040 |
Why?
|
| Prognosis | 3 | 2009 | 2093 | 0.040 |
Why?
|
| Length of Stay | 2 | 2001 | 780 | 0.040 |
Why?
|
| Saphenous Vein | 1 | 1978 | 61 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 1998 | 215 | 0.040 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1998 | 69 | 0.040 |
Why?
|
| Everolimus | 2 | 2009 | 26 | 0.040 |
Why?
|
| Muromonab-CD3 | 1 | 1997 | 8 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 1998 | 107 | 0.040 |
Why?
|
| Hospital Charges | 1 | 1997 | 60 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 1998 | 193 | 0.040 |
Why?
|
| Femoral Artery | 1 | 1978 | 139 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 1997 | 62 | 0.040 |
Why?
|
| Reoperation | 3 | 1994 | 467 | 0.040 |
Why?
|
| Rats, Inbred Strains | 4 | 1992 | 532 | 0.040 |
Why?
|
| Administration, Oral | 1 | 1998 | 411 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2003 | 1046 | 0.040 |
Why?
|
| Gardner Syndrome | 1 | 1996 | 3 | 0.040 |
Why?
|
| Fibromatosis, Aggressive | 1 | 1996 | 5 | 0.040 |
Why?
|
| Intestinal Neoplasms | 1 | 1996 | 30 | 0.030 |
Why?
|
| Alprostadil | 1 | 1996 | 20 | 0.030 |
Why?
|
| Liver Circulation | 1 | 1996 | 40 | 0.030 |
Why?
|
| Aged | 7 | 2005 | 14862 | 0.030 |
Why?
|
| Forecasting | 1 | 1997 | 277 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 1998 | 792 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 1998 | 340 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2000 | 1465 | 0.030 |
Why?
|
| Incidence | 2 | 1999 | 1603 | 0.030 |
Why?
|
| Replantation | 1 | 1995 | 8 | 0.030 |
Why?
|
| Sex Factors | 2 | 1997 | 1266 | 0.030 |
Why?
|
| APACHE | 1 | 1995 | 41 | 0.030 |
Why?
|
| Endarterectomy | 1 | 1995 | 22 | 0.030 |
Why?
|
| Prednisone | 1 | 1995 | 104 | 0.030 |
Why?
|
| Prospective Studies | 4 | 2009 | 3705 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 1995 | 951 | 0.030 |
Why?
|
| Lung | 1 | 1999 | 849 | 0.030 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 1994 | 6 | 0.030 |
Why?
|
| Homozygote | 1 | 1994 | 119 | 0.030 |
Why?
|
| Dogs | 3 | 1983 | 490 | 0.030 |
Why?
|
| Rats | 6 | 1994 | 5300 | 0.030 |
Why?
|
| Organ Preservation Solutions | 1 | 1994 | 45 | 0.030 |
Why?
|
| Heterozygote | 1 | 1994 | 174 | 0.030 |
Why?
|
| Wounds and Injuries | 1 | 1997 | 334 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 1994 | 166 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 1994 | 149 | 0.030 |
Why?
|
| Animals | 10 | 1994 | 20881 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 1995 | 215 | 0.030 |
Why?
|
| Syndrome | 1 | 1994 | 255 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 1995 | 222 | 0.030 |
Why?
|
| Kidney Neoplasms | 2 | 1993 | 206 | 0.030 |
Why?
|
| Lipoma | 1 | 1993 | 24 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 1994 | 236 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 1994 | 489 | 0.030 |
Why?
|
| Hemangioma | 1 | 1993 | 51 | 0.030 |
Why?
|
| Reperfusion Injury | 2 | 1994 | 320 | 0.030 |
Why?
|
| Mitochondria | 3 | 1994 | 643 | 0.020 |
Why?
|
| Peritoneal Dialysis | 1 | 1992 | 30 | 0.020 |
Why?
|
| Fatty Acids | 2 | 1992 | 222 | 0.020 |
Why?
|
| Subclavian Vein | 1 | 1990 | 17 | 0.020 |
Why?
|
| Vascular Patency | 2 | 2004 | 122 | 0.020 |
Why?
|
| Membrane Fluidity | 1 | 1990 | 13 | 0.020 |
Why?
|
| Double-Blind Method | 3 | 1999 | 1738 | 0.020 |
Why?
|
| Renal Circulation | 1 | 1990 | 49 | 0.020 |
Why?
|
| Organ Transplantation | 1 | 1991 | 110 | 0.020 |
Why?
|
| Catheterization, Central Venous | 1 | 1990 | 89 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 2 | 1999 | 42 | 0.020 |
Why?
|
| Perineum | 1 | 1988 | 11 | 0.020 |
Why?
|
| Fasciitis | 1 | 1988 | 30 | 0.020 |
Why?
|
| Radiography | 1 | 1990 | 572 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2007 | 87 | 0.020 |
Why?
|
| Psoriasis | 1 | 2007 | 46 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2007 | 230 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2007 | 151 | 0.020 |
Why?
|
| Sheep | 2 | 1983 | 128 | 0.020 |
Why?
|
| United States | 2 | 1999 | 7367 | 0.020 |
Why?
|
| Therapeutic Equivalency | 1 | 2005 | 21 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 567 | 0.020 |
Why?
|
| Nephritis, Hereditary | 1 | 1985 | 8 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 1995 | 4848 | 0.020 |
Why?
|
| Safety | 1 | 2005 | 145 | 0.020 |
Why?
|
| Leukopenia | 1 | 2004 | 23 | 0.020 |
Why?
|
| Uremia | 1 | 1984 | 10 | 0.020 |
Why?
|
| Antilymphocyte Serum | 1 | 2004 | 52 | 0.010 |
Why?
|
| Radio Waves | 1 | 1984 | 21 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2004 | 289 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2004 | 122 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2004 | 110 | 0.010 |
Why?
|
| Hematocrit | 1 | 1983 | 70 | 0.010 |
Why?
|
| Cardiac Output | 1 | 1983 | 133 | 0.010 |
Why?
|
| Hyperthermia, Induced | 1 | 1984 | 53 | 0.010 |
Why?
|
| Prothrombin Time | 1 | 2003 | 24 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 1983 | 122 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1983 | 93 | 0.010 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2003 | 25 | 0.010 |
Why?
|
| Adsorption | 1 | 1983 | 225 | 0.010 |
Why?
|
| Antibodies | 1 | 1983 | 241 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1983 | 525 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2003 | 249 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 1983 | 323 | 0.010 |
Why?
|
| Perfusion | 1 | 1981 | 131 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1981 | 145 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2003 | 880 | 0.010 |
Why?
|
| Hypothermia, Induced | 1 | 1981 | 93 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 2077 | 0.010 |
Why?
|
| Renal Artery | 1 | 2000 | 29 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2000 | 216 | 0.010 |
Why?
|
| Preoperative Care | 2 | 1995 | 275 | 0.010 |
Why?
|
| Oxidation-Reduction | 2 | 1992 | 567 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 1980 | 199 | 0.010 |
Why?
|
| Liver Diseases | 1 | 1999 | 193 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 1984 | 1070 | 0.010 |
Why?
|
| Hepatic Artery | 1 | 1996 | 25 | 0.010 |
Why?
|
| Portal Vein | 1 | 1996 | 46 | 0.010 |
Why?
|
| Suction | 1 | 1996 | 33 | 0.010 |
Why?
|
| Polytetrafluoroethylene | 1 | 1996 | 55 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1999 | 1745 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1996 | 172 | 0.010 |
Why?
|
| Analgesics, Opioid | 1 | 2001 | 498 | 0.010 |
Why?
|
| Registries | 1 | 1999 | 733 | 0.010 |
Why?
|
| Blood Vessel Prosthesis | 1 | 1996 | 182 | 0.010 |
Why?
|
| Mutation | 1 | 2000 | 1213 | 0.010 |
Why?
|
| Cell Compartmentation | 1 | 1994 | 41 | 0.010 |
Why?
|
| Hypertonic Solutions | 1 | 1994 | 17 | 0.010 |
Why?
|
| Raffinose | 1 | 1994 | 28 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 1995 | 124 | 0.010 |
Why?
|
| Allopurinol | 1 | 1994 | 36 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1996 | 453 | 0.010 |
Why?
|
| Cold Temperature | 1 | 1994 | 90 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1994 | 351 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 1995 | 291 | 0.010 |
Why?
|
| Adenosine | 1 | 1994 | 165 | 0.010 |
Why?
|
| Liver Failure | 1 | 1993 | 27 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1994 | 765 | 0.010 |
Why?
|
| Neoplasms | 1 | 1984 | 1667 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1992 | 36 | 0.010 |
Why?
|
| Organelles | 1 | 1992 | 18 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 1992 | 92 | 0.010 |
Why?
|
| Catalase | 1 | 1992 | 85 | 0.010 |
Why?
|
| Blotting, Western | 1 | 1994 | 954 | 0.010 |
Why?
|
| Glutathione | 1 | 1994 | 343 | 0.010 |
Why?
|
| Tissue Transplantation | 1 | 1991 | 9 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 1994 | 499 | 0.010 |
Why?
|
| Sternoclavicular Joint | 1 | 1990 | 3 | 0.010 |
Why?
|
| Insulin | 1 | 1994 | 619 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1990 | 219 | 0.010 |
Why?
|
| Catheters, Indwelling | 1 | 1990 | 72 | 0.010 |
Why?
|
| Equipment Design | 1 | 1992 | 500 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 1990 | 91 | 0.010 |
Why?
|
| Fluorescence Polarization | 1 | 1990 | 14 | 0.010 |
Why?
|
| Models, Biological | 1 | 1994 | 981 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1990 | 219 | 0.010 |
Why?
|
| Mice | 1 | 1981 | 8474 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1994 | 2083 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 1990 | 186 | 0.010 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 1988 | 48 | 0.000 |
Why?
|
| Caprylates | 1 | 1988 | 32 | 0.000 |
Why?
|
| Debridement | 1 | 1988 | 55 | 0.000 |
Why?
|
| Homeostasis | 1 | 1990 | 291 | 0.000 |
Why?
|
| Fluid Therapy | 1 | 1988 | 59 | 0.000 |
Why?
|
| Energy Metabolism | 1 | 1990 | 222 | 0.000 |
Why?
|
| Necrosis | 1 | 1988 | 239 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1992 | 2455 | 0.000 |
Why?
|
| Ethanol | 1 | 1992 | 893 | 0.000 |
Why?
|
| Splenectomy | 1 | 1985 | 40 | 0.000 |
Why?
|
| Mitomycins | 1 | 1984 | 4 | 0.000 |
Why?
|
| Ligation | 1 | 1984 | 83 | 0.000 |
Why?
|
| Bleomycin | 1 | 1984 | 67 | 0.000 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1983 | 22 | 0.000 |
Why?
|
| Hemagglutination Tests | 1 | 1983 | 16 | 0.000 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1983 | 13 | 0.000 |
Why?
|
| Immunoenzyme Techniques | 1 | 1983 | 196 | 0.000 |
Why?
|
| Erythrocytes | 1 | 1983 | 137 | 0.000 |
Why?
|
| Immunoglobulins | 1 | 1983 | 97 | 0.000 |
Why?
|
| Immunization | 1 | 1983 | 86 | 0.000 |
Why?
|
| Rabbits | 1 | 1983 | 509 | 0.000 |
Why?
|
| Hyperplasia | 1 | 1980 | 89 | 0.000 |
Why?
|
| Epithelium | 1 | 1980 | 172 | 0.000 |
Why?
|
| Muscle, Smooth | 1 | 1980 | 117 | 0.000 |
Why?
|
| Kidney Tubules | 1 | 1980 | 80 | 0.000 |
Why?
|
| Regeneration | 1 | 1980 | 105 | 0.000 |
Why?
|
| Kidney Glomerulus | 1 | 1980 | 155 | 0.000 |
Why?
|